Edwards Lifesciences Corporation (EWL) Fair Value & Analysis
Healthcare · DE · Market cap €45.9B
Fair value as of: Jul 12, 2026
From 24 valuation models · updated yesterday
Share price +10.6% over the past month.
Price vs Fair Value (7 months)
7‑month range €63.38 – €83.04 · fair‑value band €27.97 – €46.61 · the €80.86 price screens above the €37.29 fair value. As of Jul 12, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Edwards Lifesciences Corporation (EWL) currently trades at €80.86, while our model-based Fair Value estimate is €37.29 — implying the stock looks roughly 53.9% overvalued today. We read business quality at 67/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Edwards Lifesciences Corporation generated revenue of €6.3B at a net margin of 17.4%. Revenue grew 16.7% year over year. It earns a return on equity of 10.5%. The stock trades on a trailing P/E of 46.9. Fundamentals as of Jul 12, 2026
Our scenario range runs from €27.97 (bear case) to €46.61 (bull case); at €80.86, the current price sits above that range. The share trades near its 52-week high and 28% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside — at -54%, EWL screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.
About the company
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Edwards Lifesciences Corporation reported revenue of €6.1B in FY2025 versus €5.2B in FY2021, a compound +3.8%/yr. Reported net income was €1.1B in FY2025, compounding −8.1%/yr from FY2021.
Is EWL fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABL | €78.04 | €61.19 | -22% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDTC34 | R$203.91 | R$27.47 | -87% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
| DexCom, Inc DXCM | $69.07 | $65.56 | -5% |
| GE HealthCare Technologies Inc GEHC | $61.99 | $48.34 | -22% |
| Koninklijke Philips N.V 1PHIA | €24.31 | €9.97 | -59% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥141.85 | ¥147.63 | +4% |
| STERIS plc STE | $200.40 | $176.96 | -12% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Edwards Lifesciences Corporation (EWL) undervalued?
What is the fair value of EWL?
What is the quality score of EWL?
What is the revenue of Edwards Lifesciences Corporation (EWL)?
What is the net profit margin of EWL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Edwards Lifesciences Corporation analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.